Articles, guides, and regulatory updates from our community.
A 2026 review in Pharmaceutics examines BPC-157's biopharmaceutical challenges, pharmacokinetic gaps, and the barriers standing between preclinical promise and human trials.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines why BPC-157 lacks approved formulations, validated dosing, and completed Phase II trials despite 30+ years of preclinical data.
By Peptide Association Research Team